Abstract 240P
Background
The efficacy of first-line combination immuno-oncology therapy (IO) with ipilimumab plus nivolumab in metastatic renal cell carcinoma was demonstrated in the international phase III randomized CheckMate-214 trial. We also realized that the prognosis of Inter/Poor risk metastatic renal cancer could be extended in real clinical practice.
Methods
At Juntendo Univ. Hosp., Ipilimumab plus Nivolumab was used as first-line combination therapy for total 30 patients, including 27 patients with real-world Inter/Poor risk metastatic renal cell carcinoma from Jan/2019 to Aug/2023 and 3 patients enrolled in the international phase III study CheckMate-214. Efficacy in overall survival and safety, mainly immune-related adverse events(irAE), were retrospectively analyzed.
Results
Median age was 63 years (27-79), 37% (11/30) had prior nephrectomy. The most common metastatic lesions were lung (60%), bone (47%), and lymph node (37%). Three cases of hemodialysis were also included. The IMDC risk classification was Favor: Inter: Poor =2: 18: 10 cases. Total 80% (24/30) of cases were able to complete 4 cycles of ipilimumab. The average duration of IO treatment was 15.8 months (2-63). And the average duration of response was 27.3 months (2-92). During the mean follow-up period of 26.5 months (2-94), 6 cases died from cancer and 2 deaths from other causes. Among the cancer death cases, 4 of 6 cases were non-clear cell RCC. Deferred cytoreductive nephrectomy (DCN) could be performed in 2 cases in which metastatic lesions were controlled by IO-combo therapy. DCN was also performed in one patient withdrawn due to irAE, and surgical complete response (CR) was obtained. A total of 23% (7/30) had irAEs that forced IO administration to be discontinued. For irAEs of endocrine disorders, such as adrenal insufficiency and diabetes type 1, IO treatment could be continued with appropriate hormone replacement.
Conclusions
IO-Combo treatment for metastatic RCC was performed effectively and safely in Japanese patients. Surgical CR may be achieved with DCN after IO combination therapy even in poor-risk patients, but there is a possibility that Ipilimumab plus Nivolumab treatment has weak efficacy for non-clear cell RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract